KR20080108221A - 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 - Google Patents

출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 Download PDF

Info

Publication number
KR20080108221A
KR20080108221A KR1020087017988A KR20087017988A KR20080108221A KR 20080108221 A KR20080108221 A KR 20080108221A KR 1020087017988 A KR1020087017988 A KR 1020087017988A KR 20087017988 A KR20087017988 A KR 20087017988A KR 20080108221 A KR20080108221 A KR 20080108221A
Authority
KR
South Korea
Prior art keywords
pro
arg
gly
peptide
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087017988A
Other languages
English (en)
Korean (ko)
Inventor
페터 페첼바우어
라이너 헤닝
Original Assignee
피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하 filed Critical 피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하
Publication of KR20080108221A publication Critical patent/KR20080108221A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020087017988A 2005-12-23 2006-11-10 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 Ceased KR20080108221A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
ATA2067/2005 2005-12-23

Publications (1)

Publication Number Publication Date
KR20080108221A true KR20080108221A (ko) 2008-12-12

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087017988A Ceased KR20080108221A (ko) 2005-12-23 2006-11-10 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물

Country Status (14)

Country Link
US (1) US7897574B2 (cg-RX-API-DMAC7.html)
EP (2) EP2110136A3 (cg-RX-API-DMAC7.html)
JP (1) JP2009520696A (cg-RX-API-DMAC7.html)
KR (1) KR20080108221A (cg-RX-API-DMAC7.html)
CN (1) CN101365477A (cg-RX-API-DMAC7.html)
AT (2) AT502987A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006326890A1 (cg-RX-API-DMAC7.html)
CA (1) CA2634026A1 (cg-RX-API-DMAC7.html)
DE (1) DE502006004619D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331970T3 (cg-RX-API-DMAC7.html)
IL (1) IL192349A0 (cg-RX-API-DMAC7.html)
NO (1) NO20083191L (cg-RX-API-DMAC7.html)
RU (1) RU2008130413A (cg-RX-API-DMAC7.html)
WO (1) WO2007070899A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799758B2 (en) * 2006-02-23 2010-09-21 Ikaria Development Subsidiary Two, LLC Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
EP2193370A2 (en) * 2007-09-24 2010-06-09 Fibrex Medical Research & Development GmbH Methods of screening for compounds having anti-inflammatory activity
WO2012078736A2 (en) * 2010-12-09 2012-06-14 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
US20170112941A1 (en) * 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患/急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
PT1691827E (pt) 2004-06-25 2009-11-23 Fibrex Medical Res & Dev Gmbh Utilização de péptidos derivados da cadeia b beta de fibrinogénio humano para o tratamento do choque

Also Published As

Publication number Publication date
US7897574B2 (en) 2011-03-01
ES2331970T3 (es) 2010-01-21
EP1962887A2 (de) 2008-09-03
IL192349A0 (en) 2008-12-29
WO2007070899A2 (de) 2007-06-28
WO2007070899A3 (de) 2007-10-04
AT502987A1 (de) 2007-07-15
CA2634026A1 (en) 2007-06-28
NO20083191L (no) 2008-09-16
AU2006326890A1 (en) 2007-06-28
RU2008130413A (ru) 2010-01-27
EP2110136A3 (de) 2010-01-27
US20090005310A1 (en) 2009-01-01
EP2110136A2 (de) 2009-10-21
CN101365477A (zh) 2009-02-11
EP1962887B1 (de) 2009-08-19
ATE440282T1 (de) 2009-09-15
DE502006004619D1 (de) 2009-10-01
JP2009520696A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
Sandset et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.
US20050272634A1 (en) Use of erythropoietin
EA015350B1 (ru) Применение эритропоэтина в низкой дозировке для стимуляции эндотелиальных клеток-предшественников, а также для регенерации органов и замедления прогрессирования повреждений конечных органов
EP1691827B1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
EP3225252A1 (en) Treatment of bleeding with low half-life fibrinogen
CN103536610B (zh) 三七皂苷Fc的医药用途
US7897574B2 (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
KR20190111912A (ko) 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품
TWI441645B (zh) 作為新穎之局部用止血劑的活化型因子X(FXa)刺激劑
MX2008008324A (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
CN119684441B (zh) 一种衍生多肽pm6及其在抗血栓中的应用
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び/又は改善のための医薬
JP2002060345A (ja) 血液凝固能異常に係わる疾患の予防・治療剤
WO2008038777A1 (en) Therapeutic agent for disseminated intravascular coagulation syndrome
IT201900007446A1 (it) Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
WO2026006884A1 (en) Modulators of fxii-upar
WO2026048976A1 (ja) 血液凝固第x因子を含む安定な医薬組成物
JP2015063498A (ja) 新規なポリペプチド及びその用途
WO2004103397A1 (en) Compositions comprising factor viii and factor ixa for treating haemophilia
WO2022224249A1 (en) Procoagulant peptides and use thereof
De Curtis et al. A procyanidin extract prolongs bleeding time but does not prevent thrombosis in rats
JP2007262027A (ja) At−iiiによる内因性igf−1の産生誘導剤
NZ553426A (en) Use of erythropoietin for treating diabetes mellitus
JPH07138183A (ja) 胃・十二指腸疾患治療剤
AT501263A4 (de) Pharmazeutische zubereitung zur behandlung von schock

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080722

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110523

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130329

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130829

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I